For fat loss, the best-supported modern options are the GLP-1 and GLP-1/GIP medications used under medical care, with Semaglutide and Tirzepatide as the clearest examples because both are FDA-approved and sit on established pathways. Retatrutide, an investigational triple-agonist, can look stronger in trials, but promising headline data does not make it the simplest or safest default for someone new. The filter that actually matters for a beginner is not the largest percentage in a study, it is approval status, whether you have clinician oversight, how well you tolerate side effects, any contraindications you have, and whether there is a realistic maintenance plan for after the initial results. Chasing the most experimental compound because its numbers look biggest is how beginners get in over their heads. Start from what is approved and supervised, then learn the rest before going further.
Evidence-first shortlist
- Semaglutide: FDA-approved GLP-1 pathway.
- Tirzepatide: FDA-approved GLP-1/GIP pathway.
- Retatrutide: investigational triple agonist, promising but less settled.
Beginner filter
Approval status, clinician oversight, side-effect tolerance, contraindications, and maintenance plan matter more than chasing the largest headline percentage.
What to read next
Compare mechanism, side effects, approval status, and timeline before deciding what question to bring to a provider.
Membership computes it once for your exact vial and saves it, and the AI Coach answers questions about your specific stack, missed doses, timing, what to watch. from $4.99/week or $29.99 for a full cycle.
Get your exact numbers →Helpful next pages
More glp-1 answers
Want new research summaries?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Last updated 2026-08-07.